Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and increased the price target to $464.00 from $462.00.
Terence Flynn has given his Hold rating due to a combination of factors surrounding Vertex Pharmaceuticals’ recent performance and future outlook. The company’s first-quarter revenue was slightly below consensus expectations, although it was in line with Morgan Stanley’s projections. Additionally, the earnings per share were within the expected range but did not surpass consensus estimates.
Despite these mixed results, Vertex raised the lower end of its 2025 revenue guidance, indicating some optimism about future performance. However, the initial sales figures for new product launches like Alyftrek were below expectations, and Journavx sales were still building. These elements suggest a cautious approach, as the company navigates challenges such as the impact of intellectual property issues in Russia and the early stages of new product uptake.